Head of Department
Charité–Universitätsmedizin Berlin , Germany
Marcus A. Mall is Professor and Chair of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine at the Charité – University Medical Center Berlin and Professor at the Berlin Institute of Heath (BIH). He is an active member of several professional societies including the European Cystic Fibrosis Society (ECFS), the European Respiratory Society (ERS) and the American Thoracic Society (ATS). He is one of the founding Directors of the German Center for Lung Research (DZL) where he coordinates the CF research program, has been appointed Fellow of ERS (FERS) and currently serves as Associate Editor of the European Respiratory Journal.
Marcus Mall qualified in Medicine at the University of Freiburg, Freiburg, Germany, and received his clinical training at the Universities of Freiburg and Heidelberg, and his postdoctoral training at the University of North Carolina at Chapel Hill, NC, USA, where he was appointed Assistant Professor of Medicine. In 2005, he received a grant from the European Commission to establish a Marie Curie Excellence Team for CF research at the University of Heidelberg. In 2009 he was awarded the prestigious Heisenberg Professorship by the German Research Foundation and in 2018 the Einstein Professorship by the Einstein Foundation Berlin. He is board certified in Pediatrics, Pediatric Pulmonology, Allergology and Infectious Diseases.
Marcus Mall’s research is focused on the molecular and cellular pathogenesis of CF and other chronic airway diseases, and the development of novel diagnostic approaches and therapeutic strategies. His research has been funded by the German Research Foundation (DFG), the German Ministry for Education and Research (BMBF), the European Commission, and others, and he has received several research awards. During his postdoctoral research, Marcus Mall developed the first mouse model with CF-like lung disease (ENaC-overepressing mouse). His current research focus is on interdisciplinary translational research projects, integrating basic research with cohort studies and early phase clinical trials, to improve our understanding of CF lung disease and the translation of research results into the clinic.